Merck &Inc (id:8477 MRK)
98.89 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/23/2024 1:49:35 PM)
Exchange open, closes in 2 hours 10 minutes
About Merck &Inc
Market Capitalization 249.72B
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
| Headquarters (address) |
126 East Lincoln Avenue Rahway 07065 NJ United States |
| Phone | 908 740 4000 |
| Website | https://www.merck.com |
| Employees | 70K |
| Sector | Healthcare |
| Industry | Drug Manufacturers General |
| Ticker | MRK |
| Exchange | New York Stock Exchange |
| Currency | USD |
| 52 week range | 94.48 - 134.63 |
| Market Capitalization | 249.72B |
| Dividend yield forward | 3.30 % |
| Dividend yield forward United States (ID:6, base:1858) | 4.48 % |
| P/E trailing | 20.65 |
| P/E forward | 10.50 |
| Price/Sale | 3.95 |
| Price/Book | 5.62 |
| Beta | 3.00 |
| EPS | 4.78 |
| EPS United States (ID:6, base:3382) | 24.33 |
Dividend growth streak
Merck &Inc has raised their dividend 13.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Merck &Inc has raised their dividend 3.30 years in a row. This is below the 42121.954600 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Merck &Inc has raised their dividend 6.08 years in a row. This is below the 23.957000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Merck &Inc has raised their dividend 8.26 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Merck &Inc has raised their dividend 5.52 years in a row. This is below the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Merck &Inc has raised their dividend 64.44 years in a row. This is below the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
Merck &Inc years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry
Dividend growth streak
Merck &Inc has raised their dividend 13.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Merck &Inc has raised their dividend 3.30 years in a row. This is below the 42121.954600 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Merck &Inc has raised their dividend 6.08 years in a row. This is below the 23.957000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Merck &Inc has raised their dividend 8.26 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Merck &Inc has raised their dividend 5.52 years in a row. This is below the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Merck &Inc has raised their dividend 64.44 years in a row. This is below the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
Merck &Inc years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry